Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
g-MSH synthetic peptides
- Development stage
- Discontinued
- Lead developer
- Teleost Biopharmaceuticals
- Modality
- Peptides
- Administration
- Topical
01
Overview
g-MSH synthetic peptides (also known as Peptide G) are topically administered, stable synthetic analogs of gamma-melanocyte-stimulating hormone (g-MSH) developed by Teleost Biopharmaceuticals under an exclusive license from the University of Arizona. These peptides act as agonists of the melanocortin 1 receptor (MC1R) to stimulate melanin production in skin cells without requiring UV or sunlight exposure. Formulated for topical delivery (including via a patch or cosmetic creams under the Genesis Cosmeceuticals brand), they are designed to provide cosmetic skin tanning and photoprotection, helping to prevent UV-induced skin damage and related skin maladies. A licensing agreement with Anew Medical (now Klotho Neurosciences) to develop these peptides for obesity and eating disorders via MC3R/MC4R activation was terminated in November 2024.
- Brand names
- Genesis CosmeceuticalsPortofino Cosmetics
- Other names
- Genesis Cosmeceuticals skin careMelanotropin Ligands for Skin CarePeptide Gtopical cosmetic tanning peptides
02
Targets
MC1R (Melanocortin Type 1 Receptor)MC3R (Melanocortin Receptor Type 3)MC4R (Melanocortin 4 receptor)MC5R (Melanocortin 5 Receptor)
Beyond the preview
Go deeper on g-MSH synthetic peptides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on g-MSH synthetic peptides.